Sign In
Buy WHWK
$4.15
-0.250 (-5.68%)
At Close: Jun 05, 2026
PTK7 is the third most highly expressed tumor marker among clinically validated and emerging ADC targets, present in ~70% of tumors PTK7 expression is stable across histologic subtype, disease stage a
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research
08:30am, Thursday, 16'th Oct 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therap
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 02'nd Sep 2025
MORRISTOWN, N.J. , Sept. 2, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficientl
